缬沙坦治疗原发性高血压的疗效评价及对血管活性物质的影响

Effect of Valsartan in Treatment of Essential Hypertension

目的:观察缬沙坦治疗高血压的疗效及对血浆内皮素-1(ET)和降钙素基因相关肽(CGRP)的影响。方法:通过治疗45例轻-中度高血压病人,观察血压变化情况,其中25例完成了24小时动态血压监测,并测定治疗前后的ET和CGRP的水平。结果:高血压治疗组总有效率80.0％,动态血压监测结果显示:昼夜平均收缩压和舒张压明显下降,收缩压和舒张压的谷峰比值均>50％,治疗后的ET水平下降(P<0.05),CGRP显著上升(P<0.01)。结论:缬沙坦治疗轻-中度高血压有良好疗效,且对患者ET及CGRP分泌有明显改善作用。

Objective:To evaluate the effects of valsartan(Diovan, Novartis) on essential hypertension and to investigate the changes of endothelin(ET) and calcitonin gene related peptide(CGRP) after valsartan treatment. Methods: Forty five patients with mild to moderate hypertension were treated with valsartan,80mg- 160mg/d for four weeks. Ambulatory blood pressure(ABP) was monitored in twenty five cases. The plasma ET and CGRP levels in all patients were measured before and after valsartan treatment. Results: Valsartan was effective at lowering blood pressure in hypertension group, the respons rate was 80.0%. The ABPM showed that the mean SBP and DBP at day and night were lowered apparently, the trough to peak ratio of both SBP and DBP were greater than 50%. The level of plasma ET decreased(P<0.05) and that of plasma CGRP increased(P<0.01) after valsartan treatment. Conclusion: Valsartan is effective in the treatment of mild to moderate hypertension and can decrease the level of Et and increase the level of CGRP.